We found that Bortezomib-treated and inhibited (shRNA-MAGE-C1/CT7) myeloma cells showed a significant decrease in cells in the G2/M phase when compared with control cells (empty vector and ineffective shRNA). This evidence concerns the gene MAGEC1 and plasma cell myeloma.